Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
Tóm tắt
Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor control in most solid tumors. Overcoming intrinsic and/or acquired resistance may need a doublet or triplet therapy strategy. Herein, we report the safety and feasibility of dual EGFR blockade with EGFR monoclonal antibody and EGFR tyrosine kinase inhibitor combined with anti-VEGF antibody in advanced solid tumors. We conducted a phase I study combining erlotinib, cetuximab, and bevacizumab. Patients with advanced or metastatic solid tumors (excluding colorectal and non-small cell lung cancers) were analyzed for safety, toxicity profile, and response. Anti-tumor activity was evaluated per response evaluation criteria in solid tumors (RECIST 1.0). Thirty-six patients received treatment on a range of dose-levels. The most frequent tumor types enrolled were cervical (n = 10), head and neck squamous cell (n = 10), and follicular thyroid (n = 4) cancers. The most common treatment-related grade ≥ 2 adverse events were rash (56%), hypomagnesemia (17%), pruritus (11%), diarrhea (8%), and tumor-related bleeding (8%). Seventeen of 19 patients (89%) treated at the maximum tolerated dose did not present treatment-related dose-limiting toxicity. Fifteen (63%) of the 24 evaluable patients achieved a disease control (stable disease ≥ 4 months (n = 14) and partial response (n = 1). The median number of prior lines of therapies was 3 (range 1–10). The triplet combination of erlotinib, cetuximab, and bevacizumab was well tolerated, conferring clinical benefit in heavily pretreated patients. Future studies are warranted with second or third-generation EGFR tyrosine kinase triplet combinations in the EGFR pathway aberrant patients. Trial Registration: ClinicalTrials.gov Identifier: NCT00543504. Sponsor(s): National Cancer Institute (NCI), MD Anderson Cancer Center
Tài liệu tham khảo
citation_journal_title=Trends Cancer.; citation_title=Challenging standard-of-care paradigms in the precision oncology era; citation_author=V Subbiah, R Kurzrock; citation_volume=4; citation_issue=2; citation_publication_date=2018; citation_pages=101-109; citation_doi=10.1016/j.trecan.2017.12.004; citation_id=CR1
citation_journal_title=N Engl J Med; citation_title=Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children; citation_author=A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri; citation_volume=378; citation_issue=8; citation_publication_date=2018; citation_pages=731-739; citation_doi=10.1056/NEJMoa1714448; citation_id=CR2
citation_journal_title= N Engl J Med; citation_title=Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations; citation_author=DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay; citation_volume=373; citation_issue=8; citation_publication_date=2015; citation_pages=726-736; citation_doi=10.1056/NEJMoa1502309; citation_id=CR3
citation_journal_title=N Engl J Med; citation_title=Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer; citation_author=JC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, KH Lee; citation_volume=378; citation_issue=2; citation_publication_date=2018; citation_pages=113-125; citation_doi=10.1056/NEJMoa1713137; citation_id=CR4
citation_journal_title=Nat Commun.; citation_title=Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance; citation_author=H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya; citation_volume=3; citation_publication_date=2012; citation_pages=724; citation_doi=10.1038/ncomms1727; citation_id=CR5
citation_journal_title=Lancet Oncol; citation_title=Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial; citation_author=R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay; citation_volume=19; citation_issue=10; citation_publication_date=2018; citation_pages=1315-1327; citation_doi=10.1016/S1470-2045(18)30497-2; citation_id=CR6
citation_journal_title=N Engl J Med.; citation_title=Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma; citation_author=C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, E Levchenko; citation_volume=381; citation_issue=7; citation_publication_date=2019; citation_pages=626-636; citation_doi=10.1056/NEJMoa1904059; citation_id=CR7
citation_journal_title= N Engl J Med.; citation_title=Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer; citation_author=S Kopetz, A Grothey, R Yaeger, E Cutsem, J Desai, T Yoshino; citation_volume=381; citation_issue=17; citation_publication_date=2019; citation_pages=1632-1643; citation_doi=10.1056/NEJMoa1908075; citation_id=CR8
citation_journal_title=Nat Med; citation_title=Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study; citation_author=JK Sicklick, S Kato, R Okamura, M Schwaederle, ME Hahn, CB Williams; citation_volume=25; citation_issue=5; citation_publication_date=2019; citation_pages=744-750; citation_doi=10.1038/s41591-019-0407-5; citation_id=CR9
citation_journal_title=Nat Med; citation_title=Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial; citation_author=J Rodon, JC Soria, R Berger, WH Miller, E Rubin, A Kugel; citation_volume=25; citation_issue=5; citation_publication_date=2019; citation_pages=751-758; citation_doi=10.1038/s41591-019-0424-4; citation_id=CR10
citation_journal_title=Gene; citation_title=Epidermal growth factor receptor (EGFR) signaling in cancer; citation_author=N Normanno, A Luca, C Bianco, L Strizzi, M Mancino, MR Maiello; citation_volume=366; citation_issue=1; citation_publication_date=2006; citation_pages=2-16; citation_doi=10.1016/j.gene.2005.10.018; citation_id=CR11
citation_journal_title=N Engl J Med; citation_title=Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer; citation_author=E Cutsem, CH Kohne, E Hitre, J Zaluski, CR Chang Chien, A Makhson; citation_volume=360; citation_issue=14; citation_publication_date=2009; citation_pages=1408-1417; citation_doi=10.1056/NEJMoa0805019; citation_id=CR12
citation_journal_title=N Engl J Med.; citation_title=Cetuximab for the treatment of colorectal cancer; citation_author=DJ Jonker, CJ O’Callaghan, CS Karapetis, JR Zalcberg, D Tu, HJ Au; citation_volume=357; citation_issue=20; citation_publication_date=2007; citation_pages=2040-2048; citation_doi=10.1056/NEJMoa071834; citation_id=CR13
citation_journal_title=N Engl J Med.; citation_title=Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck; citation_author=JA Bonner, PM Harari, J Giralt, N Azarnia, DM Shin, RB Cohen; citation_volume=354; citation_issue=6; citation_publication_date=2006; citation_pages=567-578; citation_doi=10.1056/NEJMoa053422; citation_id=CR14
citation_journal_title=N Engl J Med.; citation_title=Platinum-based chemotherapy plus cetuximab in head and neck cancer; citation_author=JB Vermorken, R Mesia, F Rivera, E Remenar, A Kawecki, S Rottey; citation_volume=359; citation_issue=11; citation_publication_date=2008; citation_pages=1116-1127; citation_doi=10.1056/NEJMoa0802656; citation_id=CR15
citation_journal_title=N Engl J Med.; citation_title=Erlotinib in previously treated non-small-cell lung cancer; citation_author=FA Shepherd, J Rodrigues Pereira, T Ciuleanu, EH Tan, V Hirsh, S Thongprasert; citation_volume=353; citation_issue=2; citation_publication_date=2005; citation_pages=123-132; citation_doi=10.1056/NEJMoa050753; citation_id=CR16
citation_journal_title=Lancet Oncol; citation_title=Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial; citation_author=R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip; citation_volume=13; citation_issue=3; citation_publication_date=2012; citation_pages=239-246; citation_doi=10.1016/S1470-2045(11)70393-X; citation_id=CR17
citation_journal_title=J Clin Oncol; citation_title=Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer; citation_author=AJ Weickhardt, TJ Price, G Chong, V Gebski, N Pavlakis, TG Johns; citation_volume=30; citation_issue=13; citation_publication_date=2012; citation_pages=1505-1512; citation_doi=10.1200/JCO.2011.38.6599; citation_id=CR18
citation_journal_title=J Biol Chem; citation_title=Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations; citation_author=M Perez-Torres, M Guix, A Gonzalez, CL Arteaga; citation_volume=281; citation_issue=52; citation_publication_date=2006; citation_pages=40183-40192; citation_doi=10.1074/jbc.M607958200; citation_id=CR19
citation_journal_title=J Clin Invest.; citation_title=Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer; citation_author=L Regales, Y Gong, R Shen, E Stanchina, I Vivanco, A Goel; citation_volume=119; citation_issue=10; citation_publication_date=2009; citation_pages=3000-3010; citation_id=CR20
citation_journal_title=Semin Oncol; citation_title=Role of angiogenesis in tumor growth and metastasis; citation_author=J Folkman; citation_volume=29; citation_issue=6 Suppl 16; citation_publication_date=2002; citation_pages=15-18; citation_doi=10.1053/sonc.2002.37263; citation_id=CR21
citation_journal_title=N Engl J Med.; citation_title=Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer; citation_author=H Hurwitz, L Fehrenbacher, W Novotny, T Cartwright, J Hainsworth, W Heim; citation_volume=350; citation_issue=23; citation_publication_date=2004; citation_pages=2335-2342; citation_doi=10.1056/NEJMoa032691; citation_id=CR22
citation_journal_title=N Engl J med.; citation_title=A randomized trial of bevacizumab for newly diagnosed glioblastoma; citation_author=MR Gilbert, JJ Dignam, TS Armstrong, JS Wefel, DT Blumenthal, MA Vogelbaum; citation_volume=370; citation_issue=8; citation_publication_date=2014; citation_pages=699-708; citation_doi=10.1056/NEJMoa1308573; citation_id=CR23
citation_journal_title=N Engl J Med.; citation_title=Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer; citation_author=A Sandler, R Gray, MC Perry, J Brahmer, JH Schiller, A Dowlati; citation_volume=355; citation_issue=24; citation_publication_date=2006; citation_pages=2542-2550; citation_doi=10.1056/NEJMoa061884; citation_id=CR24
citation_journal_title=N Engl J Med.; citation_title=Improved survival with bevacizumab in advanced cervical cancer; citation_author=KS Tewari, MW Sill, HJ Long, RT Penson, H Huang, LM Ramondetta; citation_volume=370; citation_issue=8; citation_publication_date=2014; citation_pages=734-743; citation_doi=10.1056/NEJMoa1309748; citation_id=CR25
citation_journal_title=N Engl J Med.; citation_title=Incorporation of bevacizumab in the primary treatment of ovarian cancer; citation_author=RA Burger, MF Brady, MA Bookman, GF Fleming, BJ Monk, H Huang; citation_volume=365; citation_issue=26; citation_publication_date=2011; citation_pages=2473-2483; citation_doi=10.1056/NEJMoa1104390; citation_id=CR26
citation_journal_title=Br J Cancer; citation_title=Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors; citation_author=RM Shaheen, SA Ahmad, W Liu, N Reinmuth, YD Jung, WW Tseng; citation_volume=85; citation_issue=4; citation_publication_date=2001; citation_pages=584-589; citation_doi=10.1054/bjoc.2001.1936; citation_id=CR27
citation_journal_title=J Clin Oncol; citation_title=Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study; citation_author=LB Saltz, HJ Lenz, HL Kindler, HS Hochster, S Wadler, PM Hoff; citation_volume=25; citation_issue=29; citation_publication_date=2007; citation_pages=4557-4561; citation_doi=10.1200/JCO.2007.12.0949; citation_id=CR28
citation_journal_title=Cell; citation_title=Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development; citation_author=BM Lichtenberger, PK Tan, H Niederleithner, N Ferrara, P Petzelbauer, M Sibilia; citation_volume=140; citation_issue=2; citation_publication_date=2010; citation_pages=268-279; citation_doi=10.1016/j.cell.2009.12.046; citation_id=CR29
citation_journal_title=Nat Clin Pract Oncol; citation_title=Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications; citation_author=G Tortora, F Ciardiello, G Gasparini; citation_volume=5; citation_issue=9; citation_publication_date=2008; citation_pages=521-530; citation_doi=10.1038/ncponc1161; citation_id=CR30
citation_journal_title=Oncotarget.; citation_title=Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review; citation_author=JH Kim; citation_volume=7; citation_issue=12; citation_publication_date=2016; citation_pages=13680-13687; citation_id=CR31
citation_journal_title=Oncotarget.; citation_title=Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer; citation_author=GS Falchook, A Naing, DS Hong, R Zinner, S Fu, SA Piha-Paul; citation_volume=4; citation_issue=1; citation_publication_date=2013; citation_pages=118-127; citation_doi=10.18632/oncotarget.763; citation_id=CR32
citation_journal_title=Oncoscience.; citation_title=Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer; citation_author=GS Falchook, A Naing, JJ Wheler, AM Tsimberidou, R Zinner, DS Hong; citation_volume=1; citation_issue=8; citation_publication_date=2014; citation_pages=540-549; citation_doi=10.18632/oncoscience.73; citation_id=CR33
citation_journal_title=AJR Am J Roentgenol; citation_title=Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST; citation_author=M Nishino, JP Jagannathan, KM Krajewski, K O’Regan, H Hatabu, G Shapiro; citation_volume=198; citation_issue=4; citation_publication_date=2012; citation_pages=737-745; citation_doi=10.2214/AJR.11.7483; citation_id=CR34
citation_journal_title=Mol Cancer Ther; citation_title=Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations; citation_author=JJ Wheler, AM Tsimberidou, GS Falchook, RG Zinner, DS Hong, JY Fok; citation_volume=12; citation_issue=10; citation_publication_date=2013; citation_pages=2167-2175; citation_doi=10.1158/1535-7163.MCT-12-1208; citation_id=CR35
citation_journal_title=Lung Cancer; citation_title=Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib; citation_author=L Horn, S Gettinger, DR Camidge, EF Smit, YY Janjigian, VA Miller; citation_volume=113; citation_publication_date=2017; citation_pages=51-58; citation_doi=10.1016/j.lungcan.2017.08.014; citation_id=CR36
citation_journal_title=Oncotarget.; citation_title=Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma; citation_author=MF Setubal Destro Rodrigues, L Gammon, MM Rahman, A Biddle, FD Nunes, IC Mackenzie; citation_volume=9; citation_issue=17; citation_publication_date=2018; citation_pages=13488-13500; citation_id=CR37
citation_journal_title=Mol Cancer Res; citation_title=The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents; citation_author=J Tabernero; citation_volume=5; citation_issue=3; citation_publication_date=2007; citation_pages=203-220; citation_doi=10.1158/1541-7786.MCR-06-0404; citation_id=CR38
citation_journal_title=BMC Cancer.; citation_title=Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model; citation_author=C Ding, L Li, T Yang, X Fan, G Wu; citation_volume=16; citation_issue=1; citation_publication_date=2016; citation_pages=791; citation_doi=10.1186/s12885-016-2834-8; citation_id=CR39
citation_journal_title=Pharmacol Ther; citation_title=Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis; citation_author=AK Larsen, D Ouaret, K Ouadrani, A Petitprez; citation_volume=131; citation_issue=1; citation_publication_date=2011; citation_pages=80-90; citation_doi=10.1016/j.pharmthera.2011.03.012; citation_id=CR40
citation_journal_title=Clin Cancer Res; citation_title=EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies; citation_author=V Poindessous, D Ouaret, K Ouadrani, A Battistella, VF Megalophonos, N Kamsu-Kom; citation_volume=17; citation_issue=20; citation_publication_date=2011; citation_pages=6522-6530; citation_doi=10.1158/1078-0432.CCR-11-1607; citation_id=CR41
citation_journal_title=J clinical Oncol.; citation_title=Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib; citation_author=JD Hainsworth, JA Sosman, DR Spigel, DL Edwards, C Baughman, A Greco; citation_volume=23; citation_issue=31; citation_publication_date=2005; citation_pages=7889-7896; citation_doi=10.1200/JCO.2005.01.8234; citation_id=CR42
citation_journal_title=J Clin Oncol; citation_title=Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer; citation_author=RS Herbst, DH Johnson, E Mininberg, DP Carbone, T Henderson, ES Kim; citation_volume=23; citation_issue=11; citation_publication_date=2005; citation_pages=2544-2555; citation_doi=10.1200/JCO.2005.02.477; citation_id=CR43
citation_journal_title=Clin Cancer research : an official journal of the American Association for Cancer Res; citation_title=A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer; citation_author=MN Dickler, HS Rugo, CA Eberle, E Brogi, JF Caravelli, KS Panageas; citation_volume=14; citation_issue=23; citation_publication_date=2008; citation_pages=7878-7883; citation_doi=10.1158/1078-0432.CCR-08-0141; citation_id=CR44
citation_journal_title=Lancet Oncol; citation_title=Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial; citation_author=K Nakagawa, EB Garon, T Seto, M Nishio, S Ponce Aix, L Paz-Ares; citation_volume=20; citation_publication_date=2019; citation_pages=1655-1669; citation_doi=10.1016/S1470-2045(19)30634-5; citation_id=CR45
citation_journal_title=Clin Cancer Res; citation_title=Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer; citation_author=JY Wu, CJ Yu, YC Chang, CH Yang, JY Shih, PC Yang; citation_volume=17; citation_issue=11; citation_publication_date=2011; citation_pages=3812-3821; citation_doi=10.1158/1078-0432.CCR-10-3408; citation_id=CR46
citation_journal_title=Sci Transl Med; citation_title=Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer; citation_author=H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo; citation_volume=5; citation_issue=216; citation_publication_date=2013; citation_pages=216ra177; citation_doi=10.1126/scitranslmed.3007205; citation_id=CR47
citation_journal_title=J Thorac Oncol.; citation_title=OA 12.01 The preclinical and clinical activity of poziotinib, a potent, selective inhibitor of EGFR Exon 20 mutant NSCLC; citation_author=Y Elamin, J Robichaux, V Lam, A Tsao, C Lu, G Blumenschein; citation_volume=12; citation_issue=11; citation_publication_date=2017; citation_pages=S1776; citation_doi=10.1016/j.jtho.2017.09.394; citation_id=CR48
citation_journal_title=Cancer Res; citation_title=PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib; citation_author=JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, T Shimamura; citation_volume=67; citation_issue=24; citation_publication_date=2007; citation_pages=11924-11932; citation_doi=10.1158/0008-5472.CAN-07-1885; citation_id=CR49
citation_journal_title=Nat Med; citation_title=Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer; citation_author=JP Robichaux, YY Elamin, Z Tan, BW Carter, S Zhang, S Liu; citation_volume=24; citation_issue=5; citation_publication_date=2018; citation_pages=638-646; citation_doi=10.1038/s41591-018-0007-9; citation_id=CR50
citation_journal_title=J Thorac Oncol; citation_title=Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas; citation_author=J Eng, KM Woo, CS Sima, A Plodkowski, MD Hellmann, JE Chaft; citation_volume=10; citation_issue=12; citation_publication_date=2015; citation_pages=1713-1719; citation_doi=10.1097/JTO.0000000000000671; citation_id=CR51